Kura Oncology (NASDAQ:KURA) Insider Sells $110,087.16 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 12,314 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $110,087.16. Following the sale, the insider directly owned 158,439 shares in the company, valued at $1,416,444.66. The trade was a 7.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kura Oncology Trading Up 4.0%

KURA opened at $9.20 on Thursday. The company’s 50 day moving average price is $7.49 and its two-hundred day moving average price is $6.68. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $19.73. The firm has a market capitalization of $798.56 million, a price-to-earnings ratio of -4.07 and a beta of 0.32.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. BVF Inc. IL raised its holdings in Kura Oncology by 202.0% during the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock worth $51,177,000 after buying an additional 5,186,660 shares during the last quarter. Armistice Capital LLC raised its holdings in Kura Oncology by 13.3% during the first quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock worth $43,375,000 after buying an additional 772,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in Kura Oncology by 2.7% during the first quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company’s stock worth $32,658,000 after buying an additional 129,337 shares during the last quarter. EcoR1 Capital LLC raised its holdings in Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after buying an additional 1,559,702 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Kura Oncology by 11.7% during the second quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company’s stock worth $11,623,000 after buying an additional 211,470 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. JMP Securities reduced their price objective on shares of Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating on the stock in a research note on Monday, August 11th. Guggenheim assumed coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They issued a “neutral” rating on the stock. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Friday, June 20th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $24.10.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.